Previously Unrecognized Distinct Laryngeal Lesions During Lazertinib Therapy in EGFR-Mutated NSCLC: A Case Series
Journal of Korean Medical Science · 2026 · 41 (41)
DOI: 10.3346/jkms.2026.41.e340 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Korean Medical Science, 2026. Verfasst von Seung Heon Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Che…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seoul National University Bundang Hospital.
Abstract (Originalsprache)
Lazertinib (LECLAZA®) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC), especially in patients with brain metastases. While common adverse events such as rash and pruritus have been reported, voice-related complications and structural laryngeal lesions have not previously been reported. Here, we describe four NSCLC patients who developed new-onset voice changes or globus sensation during lazertinib-based therapy. Laryngoscopic examination revealed multifocal, broad-based polypoid mucosal thickening that was atypical for benign conditions such as contact granuloma or reflux-related disease. Histopathology in one patient demonstrated benign inflamed granulation tissue, and all lesions remained stable without interval progression over 15-36 months of follow-up. Given the small number of cases and the potential confounders, a causal association with lazertinib cannot be established. However, awareness of these benign-appearing mucosal findings may help clinicians avoid unnecessary biopsy or interruption of cancer treatment when evaluating throat or voice symptoms in patients receiving lazertinib therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
- Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. safar00@snu.ac.kr.
ORCID-Profile: Seung Heon Kang, Hyojin Kim, Jeong-Yeon Ji, Woo-Jin Jeong
Förderung
- Seoul National University Bundang Hospital
Zitieren
APA
Kang, S. H., Kim, H., Ji, J. Y., & Jeong, W. J. (2026). Previously Unrecognized Distinct Laryngeal Lesions During Lazertinib Therapy in EGFR-Mutated NSCLC: A Case Series. Journal of Korean Medical Science, 41(41). https://doi.org/10.3346/jkms.2026.41.e340
Vancouver
Kang SH, Kim H, Ji JY, Jeong WJ. Previously Unrecognized Distinct Laryngeal Lesions During Lazertinib Therapy in EGFR-Mutated NSCLC: A Case Series. Journal of Korean Medical Science. 2026;41(41). doi:10.3346/jkms.2026.41.e340
BibTeX
@article{Kang2026,
author = {Kang, Seung Heon and Kim, Hyojin and Ji, Jeong-Yeon and Jeong, Woo-Jin},
title = {Previously Unrecognized Distinct Laryngeal Lesions During Lazertinib Therapy in EGFR-Mutated NSCLC: A Case Series},
journal = {Journal of Korean Medical Science},
year = {2026},
volume = {41},
number = {41},
doi = {10.3346/jkms.2026.41.e340}
}
EUVIMED